CN105431142B - 氨基甲酸酯化合物在制备治疗猝倒的药物中的应用 - Google Patents

氨基甲酸酯化合物在制备治疗猝倒的药物中的应用 Download PDF

Info

Publication number
CN105431142B
CN105431142B CN201480027152.9A CN201480027152A CN105431142B CN 105431142 B CN105431142 B CN 105431142B CN 201480027152 A CN201480027152 A CN 201480027152A CN 105431142 B CN105431142 B CN 105431142B
Authority
CN
China
Prior art keywords
formulas
application
enantiomer
compound
dominance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480027152.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105431142A (zh
Inventor
莫伊斯·A·可罕亚拉尔罕
盖瑞·比锐恩
史帝芬·E·巴茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals International III Ltd
SK Biopharmaceuticals Co Ltd
Jazz Pharmaceuticals Inc
Original Assignee
SK Biopharmaceuticals Co Ltd
AERIAL BIOPHARMA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105431142(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Biopharmaceuticals Co Ltd, AERIAL BIOPHARMA LLC filed Critical SK Biopharmaceuticals Co Ltd
Publication of CN105431142A publication Critical patent/CN105431142A/zh
Application granted granted Critical
Publication of CN105431142B publication Critical patent/CN105431142B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480027152.9A 2013-03-13 2014-03-12 氨基甲酸酯化合物在制备治疗猝倒的药物中的应用 Active CN105431142B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
US61/778,998 2013-03-13
PCT/US2014/023969 WO2014164969A1 (en) 2013-03-13 2014-03-12 Treatment of cataplexy

Publications (2)

Publication Number Publication Date
CN105431142A CN105431142A (zh) 2016-03-23
CN105431142B true CN105431142B (zh) 2019-04-26

Family

ID=51530017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027152.9A Active CN105431142B (zh) 2013-03-13 2014-03-12 氨基甲酸酯化合物在制备治疗猝倒的药物中的应用

Country Status (21)

Country Link
US (7) US9359290B2 (enExample)
EP (1) EP2968208B1 (enExample)
JP (2) JP6530741B2 (enExample)
KR (1) KR102192554B1 (enExample)
CN (1) CN105431142B (enExample)
AU (1) AU2014248849B2 (enExample)
BR (1) BR112015022197B1 (enExample)
CA (1) CA2905457A1 (enExample)
DK (1) DK2968208T3 (enExample)
ES (1) ES2927675T3 (enExample)
HR (1) HRP20221018T1 (enExample)
HU (1) HUE060060T2 (enExample)
MX (1) MX381381B (enExample)
MY (1) MY177740A (enExample)
PH (1) PH12015502075A1 (enExample)
PT (1) PT2968208T (enExample)
RU (2) RU2689984C2 (enExample)
SG (1) SG11201507121RA (enExample)
SI (1) SI2968208T1 (enExample)
TW (2) TWI684450B (enExample)
WO (1) WO2014164969A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
US8741950B2 (en) * 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
RU2689984C2 (ru) * 2013-03-13 2019-05-30 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
EP3021838B1 (en) 2013-07-18 2020-05-27 Jazz Pharmaceuticals Ireland Limited Treatment for obesity
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
WO2018048871A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
CA3039045A1 (en) 2016-10-06 2018-04-12 Jazz Pharmaceuticals International Iii Limited Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CN111094238B (zh) 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
CN111328282A (zh) * 2017-09-12 2020-06-23 奥维德医疗公司 加波沙朵在治疗发作性睡病中的用途
WO2019148181A1 (en) 2018-01-29 2019-08-01 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CR20210514A (es) * 2018-10-15 2021-11-12 Axsome Therapeutics Inc USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
BR112022010677A2 (pt) * 2019-12-03 2022-08-16 Axsome Therapeutics Inc Uso de reboxetina para tratar transtornos do sistema nervoso
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN121620365A (zh) 2023-06-29 2026-03-06 艾克萨姆治疗股份有限公司 向哺乳期妇女施用索安非托的方法
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1656072A (zh) * 2001-04-11 2005-08-17 辉瑞大药厂 作为5－羟色胺再摄取抑制剂的苯基杂环基醚衍生物
CN1960981A (zh) * 2004-03-31 2007-05-09 詹森药业有限公司 作为组胺h3受体调节剂的非咪唑杂环化合物
CN101217949A (zh) * 2005-06-08 2008-07-09 Sk株式会社 治疗睡眠-清醒病症

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
PT873308E (pt) 1996-10-10 2002-06-28 Sk Corp Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
CA2579576A1 (en) * 2004-09-07 2006-03-16 Orphan Medical, Inc. Improved ghb compositions
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
US8552060B2 (en) 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
CN101557804A (zh) 2006-10-13 2009-10-14 詹森药业有限公司 氨基甲酸苯基烷基氨基酯组合物
DK2080012T3 (da) * 2006-11-10 2013-06-17 Dimerix Bioscience Pty Ltd Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
RU2689984C2 (ru) * 2013-03-13 2019-05-30 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1656072A (zh) * 2001-04-11 2005-08-17 辉瑞大药厂 作为5－羟色胺再摄取抑制剂的苯基杂环基醚衍生物
CN1960981A (zh) * 2004-03-31 2007-05-09 詹森药业有限公司 作为组胺h3受体调节剂的非咪唑杂环化合物
CN101217949A (zh) * 2005-06-08 2008-07-09 Sk株式会社 治疗睡眠-清醒病症

Also Published As

Publication number Publication date
RU2019114940A (ru) 2019-06-28
MX2015012644A (es) 2016-06-21
BR112015022197A2 (pt) 2017-07-18
EP2968208A4 (en) 2016-10-12
US20140275244A1 (en) 2014-09-18
BR112015022197A8 (pt) 2019-11-26
BR112015022197B1 (pt) 2022-06-07
KR20150139522A (ko) 2015-12-11
JP2016512531A (ja) 2016-04-28
RU2689984C2 (ru) 2019-05-30
US20250059135A1 (en) 2025-02-20
PT2968208T (pt) 2022-10-28
PH12015502075B1 (en) 2016-01-18
WO2014164969A1 (en) 2014-10-09
US20190218174A1 (en) 2019-07-18
RU2015143610A3 (enExample) 2018-03-21
JP2019147830A (ja) 2019-09-05
MX381381B (es) 2025-03-12
TW201919606A (zh) 2019-06-01
TW201513856A (zh) 2015-04-16
AU2014248849B2 (en) 2018-08-30
US20230416195A1 (en) 2023-12-28
DK2968208T3 (da) 2022-08-22
US12162821B2 (en) 2024-12-10
HK1219236A1 (zh) 2017-03-31
US9359290B2 (en) 2016-06-07
RU2015143610A (ru) 2017-04-20
TWI684450B (zh) 2020-02-11
PH12015502075A1 (en) 2016-01-18
CN105431142A (zh) 2016-03-23
RU2019114940A3 (enExample) 2019-12-25
JP6530741B2 (ja) 2019-06-12
US10259780B2 (en) 2019-04-16
US11072579B2 (en) 2021-07-27
EP2968208B1 (en) 2022-07-20
US11713292B2 (en) 2023-08-01
ES2927675T3 (es) 2022-11-10
HUE060060T2 (hu) 2023-01-28
US9585863B2 (en) 2017-03-07
AU2014248849A1 (en) 2015-10-08
KR102192554B1 (ko) 2020-12-18
EP2968208A1 (en) 2016-01-20
HRP20221018T1 (hr) 2023-01-06
US20220017457A1 (en) 2022-01-20
TWI663971B (zh) 2019-07-01
MY177740A (en) 2020-09-23
SI2968208T1 (sl) 2023-02-28
CA2905457A1 (en) 2014-10-09
SG11201507121RA (en) 2015-10-29
US20160250176A1 (en) 2016-09-01
US20170137375A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
CN105431142B (zh) 氨基甲酸酯化合物在制备治疗猝倒的药物中的应用
ES3040583T3 (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
US10617660B2 (en) Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
JP5881692B2 (ja) 双極性障害を治療する方法
TWI707677B (zh) 肥胖之治療
JP2019509983A (ja) 生物学的に活性なカンナビジオール類似体
TW201919605A (zh) 肥胖之治療
CN107530317A (zh) 大麻素类和n‑酰基乙醇胺的组合
CN107970209A (zh) 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法
CA2902823C (en) Intrathecal hydromorphone solutions having improved stability
JP2025508069A (ja) アチカプラントを含む組成物
CN110402142A (zh) 含局麻药的酸性乳液组合物
CN107961215A (zh) 一种左西替利嗪注射剂
JP2021152081A (ja) 医薬組成物
JP2022097835A (ja) 水中油型乳化組成物
JP2020100576A (ja) 皮膚外用組成物
CN106456598A (zh) 外用药物组合物
JP2007262031A (ja) 知覚過敏型肌掻痒感改善剤
JP7329910B2 (ja) 皮膚外用組成物
JP2020059652A (ja) タフルプロストとクエン酸エステルとを含有するデポ剤
EP4615426A1 (en) Compositions and methods for treating insomnia
CN106413699B (zh) 外用药物组合物
CN121311217A (zh) 可注射药物制剂
JP2020100575A (ja) 皮膚外用組成物
WO2020262317A1 (ja) 認知症の治療及び予防薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219236

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200327

Address after: Ai Erlandubailin

Co-patentee after: SK BIOPHARMACEUTICALS Co.,Ltd.

Patentee after: JAZZ PHARMACEUTICALS, Inc.

Address before: Hamilton, Bermuda

Co-patentee before: SK BIOPHARMACEUTICALS Co.,Ltd.

Patentee before: JAZZ PHARMACEUTICALS INTERNATIONAL III Ltd.

Effective date of registration: 20200327

Address after: Hamilton, Bermuda

Co-patentee after: SK BIOPHARMACEUTICALS Co.,Ltd.

Patentee after: JAZZ PHARMACEUTICALS INTERNATIONAL III Ltd.

Address before: North Carolina, USA

Co-patentee before: SK BIOPHARMACEUTICALS Co.,Ltd.

Patentee before: AERIAL BIOPHARMA LLC